Introduction
Pemphigus is a life-threatening autoimmune blistering disease characterized by the production of autoantibodies against desmoglein 1 (Dsg1) and/or desmoglein 3 (Dsg3).1 These antibodies target epidermal desmosomes, leading to the loss of cell-to-cell adhesion and resulting in extensive blisters and erosions on the skin and mucous membranes. While systemic corticosteroids and traditional immunosuppressants have long been the mainstay of treatment, they are often associated with limited complete remission rates, prolonged treatment durations, and significant side effects, which cause a major clinical challenge.1,2
Rituximab (RTX) is a chimeric monoclonal antibody targeting CD20+ B cells, which has revolutionized the management of pemphigus. Although standard-dose RTX(SDRTX, 1000 mg) is effective, it is frequently associated with severe adverse events, including infusion reactions and infections such as pneumonia.3 For refractory pemphigus patients with prior malignant tumor resection and steroid induced adverse events, SDRTX may lead to excessive immunosuppression and raise risks of infection and tumor recurrence, leaving limited therapeutic options in clinical practice. Consequently, finding an optimal balance between therapeutic efficacy and safety has become a focal point of recent research.
Recent studies have begun to explore lower dosing regimens. Notably, a 52-week clinical trial by Cao et al demonstrated that ultra-low-dose rituximab (ULRTX, 100 mg) achieved comparable B cell depletion and disease control to standard doses, while reducing costs and the incidence of adverse events.4,5
In this report, we present a 73‑year‑old male patient with refractory, steroid-intolerant pemphigus vulgaris (PV). The patient experienced recurrent flares and could not achieve persistent disease control under prior glucocorticoid treatment.
Case Report
A 73‑year‑old male patient presented with a one-year history of recurrent erythema, blisters and bullae distributed over the scalp, neck and back, accompanied by severe pruritus and persistent recurrent oral mucosal ulcers. Skin biopsy and serological testing at an outside hospital confirmed PV, with positive serum anti-desmoglein 1 and anti-desmoglein 3 antibodies detected. His medical history was complicated by multiple malignant tumors and steroid related adverse complications.
He underwent radical colon cancer resection 15 years ago and lung cancer resection 6 years ago, with regular long-term outpatient surveillance ever since. The patient’s previous therapeutic journey was characterized by repeated disease flares and unsatisfactory treatment responses. The patient initially received oral methylprednisolone 32 mg once daily, which rapidly controlled his cutaneous lesions.
Prophylactic agents including omeprazole, hydrotalcite, potassium chloride and calcium carbonate were concurrently administered to mitigate glucocorticoid related adverse effects. Nevertheless, severe acute gastrointestinal hemorrhage developed five months before admission, accompanied by newly diagnosed osteoporosis. Glucocorticoid therapy was therefore withdrawn.
Three months after discontinuation of glucocorticoids, the patient experienced a cutaneous flare up, and oral methylprednisolone 32 mg daily was restarted. Nevertheless, new blisters continued to emerge. The patient then presented to our department for further management, and Figure 1 shows his cutaneous manifestations at that time.
Figure 1Clinical manifestations of the patient before rituximab treatment: generalized erythema covered with yellow serous crusts and scattered erosions on the trunk and proximal limbs.Two images showing the patient’s trunk and proximal limbs before rituximab treatment, with extensive erythema, yellow serous crusts, and scattered erosions.
Cutaneous physical examination identified scattered erythema covered with dry yellow serous crusts on the scalp, trunk and proximal extremities, with residual erosions visible after crust detachment. Nikolsky sign was positive. Serological testing revealed that both Dsg1 and Dsg3 antibody levels exceeded 200.0 RU/mL.
Peripheral lymphocyte subsets were assessed by flow cytometry, with B cells defined as CD3−CD19⁺ lymphocytes. At baseline, the absolute peripheral B-cell count was 179.74/µL, accounting for 6.55% of total peripheral lymphocytes.
Given inadequate disease control with monotherapy of methylprednisolone and the patient’s prior history of severe glucocorticoid-related adverse events, we initiated add-on ULRTX therapy while maintaining the current dose of methylprednisolone. Noticeable clinical benefits emerged 7 days after the initial administration: intractable pruritus was greatly relieved, the reepithelialization of skin erosions was significantly accelerated, and oral mucosal ulcers were nearly fully healed. Repeat lymphocyte subset assessment was performed 2 weeks after the first RTX infusion.
The absolute peripheral B-cell count was 1/µL, accounting for 0.05% of total peripheral lymphocytes, indicating that ULRTX was sufficient to achieve profound B cell depletion. The second consolidation infusion of 100 mg RTX was administered 2 weeks after the first dose, and no acute infusion related adverse reactions were observed during or after the whole procedure. After completing two rounds of ULRTX, the patient was discharged on oral methylprednisolone 28 mg daily for maintenance.
The glucocorticoid was tapered by 4 mg each month, reaching 16 mg daily after three months. A further 2 mg reduction was implemented three months later, bringing the maintenance dose down to 14 mg daily by the six-month mark.
Six months later, a detailed assessment was conducted on the patient again. The patient denied any new blisters, red plaques or mucosal erosions over those six months of monitoring (Figure 2). Dsg1 and Dsg3 antibody levels decreased to the negative range, with Dsg1 <2 RU/mL and Dsg3 4 RU/mL.
The absolute peripheral B-cell count was 2.83/µL, accounting for 0.20% of total peripheral lymphocytes. To maintain a rash-free state following further glucocorticoid tapering, the patient was re-administered 100 mg of RTX. Figure 2Clinical manifestations of the patient six months after initial rituximab treatment: scattered dark red patches and hyperpigmentation on the trunk and proximal limbs.Two images showing the patient’s trunk and proximal limbs six months after rituximab treatment, with scattered dark red patches and hyperpigmentation.
Discussion
In this report, the patient received ULRTX in addition to ongoing systemic glucocorticoid therapy. Following this intervention, complete cutaneous remission was observed; serum Dsg1 and Dsg3 seroconverted to negative levels, peripheral B lymphocytes underwent profound depletion, and oral glucocorticoid was safely tapered gradually. Neither infusion associated hypersensitivity nor serious infectious adverse events were documented.
This case suggests that ULRTX may represent a feasible and well-tolerated treatment option for high-risk patients with refractory PV and multiple comorbidities. Marked peripheral B-cell depletion was observed during the 6-month follow-up, with the absolute B-cell count decreasing from 179.74/µL at baseline to 1.00/µL 2 weeks after the first RTX infusion and remaining low at 2.83/µL at 6 months. However, the relatively short follow-up period limits conclusions regarding the long-term efficacy, safety, and B-cell repopulation after ULRTX treatment.
These findings not only validate the efficacy of ULRTX regimens in refractory PV but also provide a highly valuable personalized therapeutic paradigm for elderly or frail patients with severe comorbidities.6,7
As an anti-CD20 monoclonal antibody, the core mechanism of RTX involves specific binding to the CD20 antigen on B cells, inducing apoptosis via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC).8 Notably, RTX can effectively block the source of new pathogenic Dsg antibody production by thoroughly depleting the precursor B cell pool.9,10 The marked reduction in peripheral B-cell counts following ULRTX suggests that a 100-mg dose was sufficient to induce substantial peripheral B-cell depletion in this patient. This depletion was accompanied by a marked decline in anti-Dsg1 and anti-Dsg3 antibody levels and clinical improvement.
Notably, the patient presented with several serious concurrent conditions, including steroid-triggered gastrointestinal bleeding and osteoporosis. Standard treatment relying on long-term high-dose steroids plus traditional immunosuppressants such as mycophenolate mofetil carry significant safety risks for such patients. While systemic corticosteroids rapidly suppress inflammation, their long-term use leads to infections, metabolic disturbances, and skeletal damage, which are major contributors to mortality in patients with PV.8 In contrast, ULRTX was well tolerated in this patient during the 6-month follow-up.
The absence of infusion related adverse events observed in this study suggests the advantage of ultra-low-dose regimens in reducing the risk of acute immune reactions. Furthermore, by avoiding long-term high-dose steroid use, the risks of recurrent gastrointestinal bleeding and further deterioration of osteoporosis were significantly mitigated. Recent cohort studies also suggest that compared to traditional azathioprine/mycophenolate mofetil, the therapy of RTX confers potential advantages in long-term cardiovascular and metabolic outcomes.
By precisely targeting B cells, it avoids broad suppression of the overall immune system.11 For patients with a history of malignancy, avoiding widespread immunosuppression is particularly crucial, as it may lower the risk of secondary malignancies or recurrent infections.12
Rapid improvement of the patient’s skin and mucosal lesions closely paralleled falling anti-Dsg antibody titers and persistently low peripheral B cell counts. Anti-Dsg1 and anti-Dsg3 IgG serve as both diagnostic markers for PV and critical biomarkers reflecting disease activity and relapse risk.13,14 Pemphigus relapses arise from residual autoreactive B cells or reactivated CD20-positive B cells after depletion therapy. Major relapse risk factors include widespread baseline lesions, high BMI, elevated initial disease index, delayed treatment, and sustained high anti-Dsg1/3 antibody levels.13 Therefore, serial monitoring of peripheral B cell counts and serum anti-Dsg1/3 antibody titers is essential to evaluate therapeutic response and identify patients at high risk of relapse early.
One limitation of this case report is the relatively short duration of follow-up. Accordingly, long-term outcomes cannot be fully assessed, and further observation is warranted.
Conclusion
In conclusion, this case suggests that a 100 mg ULRTX regimen may be a feasible and well-tolerated therapeutic option for this high-risk refractory PV patient. The regimen was associated with profound B-cell depletion and rapid clinical improvement during the 6-month follow-up, while methylprednisolone was gradually tapered. Future large-scale multicenter randomized controlled trials are needed to further establish the standard status of ULRTX in specific high-risk PV populations and to explore precise dosing algorithms based on B cell subset monitoring.